Основная статистика
| CIK | 1671858 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Silverback Therapeutics Inc
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 13, 2025 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commissio |
|
| August 13, 2025 |
August 2025 neffy – the transformative needle-free solution for severe allergic reactions Exhibit 99. |
|
| August 13, 2025 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CO-PROMOTION AGREEMENT This Co-Promotion Agreement (this “Agreement”) is entered into as of May 2, 2025 (the “Effective Date”), by and betwee |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 13, 2025 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commissio |
|
| August 13, 2025 |
Exhibit 10.3 THIRD AMENDMENT TO MANUFACTURING AGREEMENT This Third Amendment to Manufacturing Agreement (this “Amendment”), effective as of July 10, 2025 (the “Third Amendment Effective Date”), is made by and between ARS Pharmaceuticals Operations, Inc. formerly known as ARS Pharmaceuticals, Inc., a corporation organized under the laws of the State of California with an office at 11682 El Camino R |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharmac |
|
| August 13, 2025 |
Exhibit 99.1 ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) $15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with additional near-term growth anticipated from national direct-to-consumer |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 25, 2025 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharma |
|
| May 14, 2025 |
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U. |
|
| May 14, 2025 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.1 ARS Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Amended Effective: April 1, 2025 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of ARS Pharmaceuticals, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensati |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2025 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission F |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 2, 2025 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 20, 2025 |
Exhibit 10.30 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Renaissance December 6, 2024 CONFIDENTIAL By E-Mail Attn: Brian Dorsey ARS Pharmaceuticals Operations, Inc. 11682 El Camino Real, Suite 120 San Diego, CA 9213 |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 20, 2025 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| March 20, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 20, 2025 |
Exhibit 10.27 Confidential EXECUTION VERSION CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION, LICENSE AND DISTRIBUTION AGREEMENT This Collaboration, License And Distribution Agreement (the |
|
| March 20, 2025 |
Exhibit 99.1 ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing 15 kilograms to < 30 kilograms (33 lbs. to < 66 lbs.), expanding the reach |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharmaceuti |
|
| March 20, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 ARS Pharmaceuticals, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per share to be issued pursuant to the ARS Pharmac |
|
| March 20, 2025 |
Exhibit 19.1 Ars Pharmaceuticals, Inc. Insider Trading Policy Persons Covered This Insider Trading Policy of ARS Pharmaceuticals, Inc. (the “Company”) applies to all directors, officers, other employees and consultants of the Company and any subsidiaries. It also applies to their family members who reside with them, anyone else who lives in their households and any family members who do not live i |
|
| March 20, 2025 |
Exhibit 10.29 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ARS Supply Agreement 1.1 This ARS Supply Agreement (“Agreement”), effective as of the Effective Date (as defined below), is by and between A |
|
| March 20, 2025 |
Exhibit 10.28 Confidential EXECUTION VERSION CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COMMERCIAL SUPPLY AGREEMENT This Commercial Supply Agreement (“Agreement”) is entered into as of November 9, |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 5, 2025 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| January 31, 2025 |
As filed with the Securities and Exchange Commission on January 31, 2025 Table of Contents As filed with the Securities and Exchange Commission on January 31, 2025 Registration No. |
|
| January 31, 2025 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.7 ARS PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF EXHIBIT 4.7 ARS PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ARS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association |
|
| January 31, 2025 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 ARS PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF EXHIBIT 4.5 ARS PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ARS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association |
|
| January 31, 2025 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.4 ARS PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF EXHIBIT 4.4 ARS PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between ARS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organiz |
|
| January 31, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) ARS Pharmaceuticals, Inc. |
|
| January 31, 2025 |
Exhibit 1.2 ARS Pharmaceuticals, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement January 31, 2025 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: ARS Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1 |
|
| January 31, 2025 |
Form of Indenture, between registrant and one or more trustees to be named. Exhibit 4.8 ARS Pharmaceuticals, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 S |
|
| January 13, 2025 |
Exhibit 99.1 ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray) Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an operating runway of at least three years Company to pre |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 13, 2025 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commissi |
|
| January 13, 2025 |
43rd Annual J.P. Morgan Healthcare Conference January 2025 neffy – the transformative needle-free solution for severe allergic reactions NASDAQ: SPRY Exhibit 99.2 Forward-looking statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements i |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File |
|
| November 18, 2024 |
ARS Pharmaceuticals, Inc., 11682 El Camino Real, Suite 120, San Diego, CA 92130 November 18, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Bonnie Baynes Mary Mast Re: ARS Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 File No. 001-39756 Dear Bonnie Baynes and Mary Mast: We are writing in response to the comment received from the staff ( |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Ph |
|
| November 13, 2024 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO MANUFACTURING AGREEMENT This Second Amendment to Manufacturing Agreement (this “Amendment”), effective as of September 17, 2024 (the “Secon |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 13, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commiss |
|
| November 13, 2024 |
Exhibit 99.1 ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates Commercial launch of neffy® (epinephrine nasal spray) underway in the United States Supplemental NDA for neffy® 1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025 Exclusive license agreement with ALK-Abelló to commercialize neffy® in Europe, Canada and certain o |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commissi |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 8, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commissio |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 17, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commis |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2024 |
Exhibit 99.1 ARS Update neffy® Approval August 12, 2024 Forward-looking statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: the design and potential benefits of |
|
| August 6, 2024 |
Exhibit 99.1 ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results neffy® (epinephrine nasal spray) New Drug Application (NDA) under review by FDA; discussions are ongoing to finalize labeling with FDA; PDUFA date in early October 2024 EURneffy® (adrenaline nasal spray) recommended for approval by EMA’s CHMP; formal marketing authorization anticipated i |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharmac |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2024 |
Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.1 ARS Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Amended Effective: June 28, 2024 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of ARS Pharmaceuticals, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensati |
|
| June 28, 2024 |
ARS Corporate Presentation June 28, 2024 Exhibit 99.1 Forward-looking statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: the anticipated timing for regulatory |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 28, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 27, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| June 28, 2024 |
ARS Corporate Presentation June 28, 2024 Exhibit 99.1 Forward-looking statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: the anticipated timing for regulatory |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 20, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| June 17, 2024 |
SC 13D/A 1 d854552dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* ARS Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 82835W 108 (CUSIP Number) Kathleen Scott ARS Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego, CA 92130 (858) 771-9 |
|
| June 11, 2024 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2024 |
ARS Corporate Presentation Q2 2024 Exhibit 99.1 Forward Looking Statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: the anticipated timing for regulatory review |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharma |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 9, 2024 |
Exhibit 99.1 ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results neffy® (epinephrine nasal spray) New Drug Application (NDA) and CRL response under review by FDA with anticipated review completion by early October 2024 Response submitted for neffy Marketing Authorization Application (MAA) to EMA’s CHMP; CHMP opinion expected in the second quart |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 29, 2024 |
SPRY / ARS Pharmaceuticals, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2410240d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARS Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 82835W 10 8 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, |
|
| March 21, 2024 |
As filed with the Securities and Exchange Commission on March 21, 2024 S-8 As filed with the Securities and Exchange Commission on March 21, 2024 Registration No. |
|
| March 21, 2024 |
Subsidiaries of the registrant. Exhibit 21.1 ARS PHARMACEUTICALS, INC. Name of Subsidiary Jurisdiction ARS Pharmaceuticals Operations, Inc. Delaware ARS Pharmaceuticals IRL, Limited Ireland |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharmaceuti |
|
| March 21, 2024 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 ARS Pharmaceuticals, Inc. |
|
| March 21, 2024 |
Incentive Compensation Recoupment Policy. Exhibit 97.1 ARS PHARMACEUTICALS, INC. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Poli |
|
| March 21, 2024 |
Exhibit 99.1 ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Preparing to submit response to the FDA’s CRL for neffy®(epinephrine nasal spray) in Type 1 allergic reactions in early Q2 2024, following successful completion of neffy repeat dose nasal allergen challenge study and nitrosamine assessments, with expected up to six-month review |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 21, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| March 21, 2024 |
Non-Employee Director Compensation Policy, as amended. Exhibit 10.9 ARS Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Amended Effective: December 6, 2022 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of ARS Pharmaceuticals, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compens |
|
| March 7, 2024 |
Exhibit 99.1 neffy Investor Day March 7, 2024 Forward Looking Statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: ARS Pharma’s plan to file its NDA early in the |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 7, 2024 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2023 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commissi |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Ph |
|
| November 9, 2023 |
Exhibit 99.1 ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates Company is on track with ongoing repeat-dose study under allergen-induced allergic rhinitis conditions requested by U.S. FDA with topline data expected in Q1 2024 Resubmission of New Drug Application (NDA) for neffy anticipated in H1 2024 Ended third quarter with $241.9 million in cash, cash |
|
| September 25, 2023 |
ARS Corporate Presentation Q4 2023 Exhibit 99.1 Forward looking statements This presentation contains forward-looking statements which include, but are not limited to, statements regarding: ARS’s ability to complete the newly required trial and provide the additional information requested by the FDA in the CRL on the timing anticipated, or at all; the potential approval of neffy and the expected t |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 25, 2023 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commis |
|
| September 25, 2023 |
SBTX / Silverback Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82835W 10 8 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Pe |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 19, 2023 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commis |
|
| September 1, 2023 |
SBTX / Silverback Therapeutics Inc / Bell Robert G. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| August 31, 2023 |
SBTX / Silverback Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) ARS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82835W 10 8 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Peter |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2023 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commissio |
|
| August 10, 2023 |
Exhibit 99.1 ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates ARS continues engagement with U.S. FDA on final labeling and post-marketing commitments for the neffy® new drug application; PDUFA target action date set for September 19, 2023 Ended second quarter with $252.2 million in cash, cash equivalents and short-term investments; well-capitalized to support anticip |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharmac |
|
| August 10, 2023 |
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| June 28, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 27, 2023 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 16, 2023 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission F |
|
| May 16, 2023 |
EX-99.1 THE FIRST NO-NEEDLE, NO-INJECTION SOLUTION for Type I Allergic Reactions Q2 2023 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements which include, but are not limited to, statements regarding the design and potential benefits of neffy; the anticipated Prescription Drug User Fee Act (PDUFA) date for neffy; the timing of regulatory approval for and |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharma |
|
| May 15, 2023 |
Exhibit 99.1 ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment of Allergic Reactions (Type I), Including Anaphylaxis New Drug and Marketing Authorization Applications for neffy Under Review with FDA and EMA, Respectively; FDA PDUFA Target Action Date Anticip |
|
| May 15, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2023 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission F |
|
| May 9, 2023 |
EX-99.1 Exhibit 99.1 FDA Briefing Document NDA/BLA# 214697 Drug name: ARS-1 (intranasal epinephrine) Applicant: ARS Pharmaceuticals Pulmonary-Allergy Drug Advisory Committee Meeting FDA has posted an Addendum to Briefing Document on its website that was circulated to members of the AdCom May 11, 2023 Division of Pulmonology, Allergy, and Critical Care Office of Immunology and Inflammation Office o |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2023 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 1, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 1, 2023 |
ARS Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego, California 92130 CORRESP ARS Pharmaceuticals, Inc. 11682 El Camino Real, Suite 120 San Diego, California 92130 May 1, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Joshua Gorsky Re: ARS Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-271359 Acceleration Request Requested Date: |
|
| April 20, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ARS Pharmaceuticals, Inc. |
|
| April 20, 2023 |
As filed with the Securities and Exchange Commission on April 20, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 20, 2023 Registration No. |
|
| March 23, 2023 |
Exhibit 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. TERMINATION AGREEMENT THIS TERMINATION AGREEMENT (the “Agreement”) is entered into as of February 22, 2023 (the “Termination Agreement Effective Date”), by and between ARS PHARMA |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 23, 2023 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| March 23, 2023 |
Exhibit 10.21 ARS PHARMACEUTICALS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for ALEXANDER A. FITZPATRICK This Executive Employment Agreement (this “Agreement”) is made and entered into effective as of December 1, 2022 (the “Effective Date”), by and between Alexander A. Fitzpatrick (“Executive”) and ARS Pharmaceuticals, Inc. (the “Company”). 1. Employment by the Company. 1.1 Position. Executive’s employ |
|
| March 23, 2023 |
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA and EMA; FDA PDUFA Target Action Date Anticipated in Mid-2023 Strong Financial Position with $274. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 ARS Pharmaceuti |
|
| March 23, 2023 |
Exhibit 10.8 ARS Pharmaceuticals, Inc. Change in Control and Severance Benefit Plan Approved by the Board of Directors: November 6, 2020 Section 1. Introduction. The ARS Pharmaceuticals, Inc. Change in Control and Severance Benefit Plan (the “Plan”) was established effective upon the IPO Date. The purpose of the Plan is to provide for the payment of severance and/or change in control benefits to e |
|
| March 23, 2023 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SILVERBACK THERAPEUTICS, INC. Laura Shawver, Ph.D., hereby certifies that: ONE: She is the duly elected Chief Executive Officer of Silverback Therapeutics, Inc., a Delaware corporation. TWO: The date of filing the original Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware was January 4, |
|
| March 23, 2023 |
Exhibit 4.3 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of ARS Pharmaceuticals, Inc. (“we,” “our” or “us”) is based on the provisions of our amended and restated certificate of incorporation, as amended (our “amended and restated certificate of incorporation”), as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Co |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 13, 2023 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commission |
|
| March 13, 2023 |
EX-99.1 Exhibit 99.1 THE FIRST NO-NEEDLE, NO-INJECTION SOLUTION for Type I Allergic Reactions Q1 2023 1 Forward looking statements This presentation contains forward-looking statements which include, but are not limited to, statements regarding the design and potential benefits of neffy; the anticipated Prescription Drug User Fee Act (PDUFA) date for neffy; the timing of regulatory approval for an |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2023 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2023 |
SBTX / Silverback Therapeutics Inc / NEXTECH VI ONCOLOGY SCSP - SC 13G/A Passive Investment SC 13G/A 1 tm236482d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARS Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82835W 10 8 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stateme |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 14, 2023 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2023 |
EX-99.1 THE FIRST NO-NEEDLE, NO-INJECTION SOLUTION for Type I Allergic Reactions Q1 2023 Exhibit 99.1 Forward looking statements This presentation contains forward-looking statements which include, but are not limited to, statements regarding the design and potential benefits of neffy; the anticipated Prescription Drug User Fee Act (PDUFA) date for neffy; the timing of regulatory approval for and |
|
| February 13, 2023 |
SBTX / Silverback Therapeutics Inc / K2 PRINCIPAL FUND, L.P. Passive Investment SC 13G/A 1 SPRY13G20230213.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Rule 13d-102) Amendment No. 1 Under the Securities Exchange Act of 1934 ARS Pharmaceuticals Inc fka Silverback Therapeutics Inc (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82835W108 (CUSIP Number) December 31, 2022 (Date of Event which |
|
| January 17, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 ARS Pharmaceuticals, Inc. Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per share to be issued pursuant to the ARS Pharmaceutica |
|
| January 17, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS EX-99.3 5 d448105dex993.htm EX-99.3 Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS On July 21, 2022, Silverback Therapeutics, Inc. (“Silverback”) entered into an agreement and plan of merger and reorganization (the “Merger Agreement”) with ARS Pharmaceuticals, Inc. (“ARS Pharma”) and Sabre Merger Sub, Inc. a Delaware corporation and wholly owned subsidiary of Silverback ( |
|
| January 17, 2023 |
Exhibit 99.1 ARS PHARMACEUTICALS, INC. 2018 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: September 14, 2018 APPROVED BY THE STOCKHOLDERS: September 14, 2018 AS AMENDED BY THE BOARD OF DIRECTORS: March 31, 2019 AS AMENDED BY THE STOCKHOLDERS: March 31, 2019 AS AMENDED BY THE BOARD OF DIRECTORS: August 25, 2021 AS AMENDED BY THE STOCKHOLDERS: August 25, 2021 TERMINATION DATE: September 1 |
|
| January 17, 2023 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EX-99.1 3 d448105dex991.htm EX-99.1 Exhibit 99.1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and the Board of Directors of ARS Pharmaceuticals, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of ARS Pharmaceuticals, Inc. (the Company) as of December 31, 2021 and December 31, 2020, the related consolidated stateme |
|
| January 17, 2023 |
EX-99.2 5 d443449dex992.htm EX-99.2 Exhibit 99.2 ARS PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2018 EQUITY INCENTIVE PLAN) ARS Pharmaceuticals, Inc. (the “Company”), pursuant to its 2018 Equity Incentive Plan (as amended and/or restated as of the Date of Grant set forth below, the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock |
|
| January 17, 2023 |
EX-99.2 4 d448105dex992.htm EX-99.2 Exhibit 99.2 ARS Pharmaceuticals, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value and share amounts) September 30, 2022 (unaudited) December 31, 2021 Assets Current assets: Cash and cash equivalents $ 37,322 $ 60,063 Other receivables 328 — Prepaid expense and other current assets 661 667 Deferred transaction costs 784 — Total current |
|
| January 17, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 4, 2022 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commis |
|
| January 17, 2023 |
As filed with the Securities and Exchange Commission on January 17, 2023 S-8 1 d443449ds8.htm S-8 As filed with the Securities and Exchange Commission on January 17, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 81-1489190 (State or other jurisdiction of incorporat |
|
| December 9, 2022 |
Exhibit 10.1 ARS PHARMACEUTICALS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for BRIAN T. DORSEY This Executive Employment Agreement (this ?Agreement?) is made and entered into effective as of October 1, 2018 (the ?Effective Date?), by and between Brian T. Dorsey (?Executive?) and ARS Pharmaceuticals, Inc. (the ?Company?). 1. Employment by the Company. 1.1 Position. Executive shall serve as the Company?s |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 6, 2022 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commissi |
|
| December 6, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 6, 2022 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commissi |
|
| December 6, 2022 |
THE FIRST NO-NEEDLE, NO-INJECTION SOLUTION for Type I Allergic Reactions December 6, 2022 Exhibit 99. |
|
| November 30, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated November 8, 2022, with respect to the common stock of ARS Pharmaceuticals, Inc. |
|
| November 30, 2022 |
SBTX / Silverback Therapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARS Pharmaceuticals, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 82835W108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-64 |
|
| November 21, 2022 |
EX-99.A Exhibit A AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 21, 2022 TABLE OF CONTENTS Page SECTION 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 2 1.3 Closing; Effective Time 2 1.4 Ce |
|
| November 21, 2022 |
SBTX / Silverback Therapeutics Inc / Bell Robert G. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 ARS Pharmaceuticals, Inc. |
|
| November 18, 2022 |
SBTX / Silverback Therapeutics Inc / Flynn James E Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 24.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13D-2(a) (Amendment No. )* ARS Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82835W108 (CUSIP Number) David Clark Elliot Press D |
|
| November 18, 2022 |
Lock-Up Agreement July 21, 2022 EX-B Exhibit B Lock-Up Agreement July 21, 2022 Ladies and Gentlemen: The undersigned (the “Stockholder”) understands that: (i) SILVERBACK THERAPEUTICS, INC. |
|
| November 18, 2022 |
Exhibit 99.1 The undersigned agree that this Schedule 13D, and all amendments thereto, relating to the Common Stock of ARS Pharmaceuticals, Inc. shall be filed on behalf of the undersigned. DEERFIELD MGMT III, L.P. By: J.E. Flynn Capital III, LLC, General Partner By: /s/ Jonathan Isler Name: Jonathan Isler Title: Attorney-in-Fact DEERFIELD PRIVATE DESIGN FUND III, L.P. By: Deerfield Mgmt III, L.P. |
|
| November 18, 2022 |
EX-A Exhibit A AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC. |
|
| November 18, 2022 |
Lock-Up Agreement July 21, 2022 EX-B Exhibit B Lock-Up Agreement July 21, 2022 Ladies and Gentlemen: The undersigned (the “Stockholder”) understands that: (i) SILVERBACK THERAPEUTICS, INC. |
|
| November 18, 2022 |
EX-A Exhibit A AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC. |
|
| November 18, 2022 |
EX-A Exhibit A AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC. |
|
| November 18, 2022 |
Lock-Up Agreement July 21, 2022 EX-B Exhibit B Lock-Up Agreement July 21, 2022 Ladies and Gentlemen: The undersigned (the “Stockholder”) understands that: (i) SILVERBACK THERAPEUTICS, INC. |
|
| November 18, 2022 |
SBTX / Silverback Therapeutics Inc / Lowenthal Richard E - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ARS Pharmaceuticals, Inc. |
|
| November 18, 2022 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ARS Pharmaceuticals, Inc. |
|
| November 18, 2022 |
SBTX / Silverback Therapeutics Inc / Tanimoto Sarina - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ARS Pharmaceuticals, Inc. |
|
| November 8, 2022 |
Exhibit 10.11 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (hereinafter ?Agreement?) is made as of the 26 April 2021 (?Effective Date?), between ARS Pharmaceuticals, Inc. (?Company?) and Brent L. Saunders (?Consultant?). Company and Consultant also are each referred to herein individually as ?Party? and collectively as the ?Parties.? BACKGROUND The Company has products in development and is seek |
|
| November 8, 2022 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. Confidential LICENSE AGREEMENT between ARS PHARMACEUTICALS, INC. and AEGIS THERAPEUTICS, LLC Effective Date as of June 18, 2018 TABLE OF CONTENTS Page 1.??DEFINITIONS 1 2.??REPRES |
|
| November 8, 2022 |
Exhibit 10.5 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. MANUFACTURING AGREEMENT BY AND BETWEEN RENAISSANCE LAKEWOOD, LLC AND ARS PHARMACEUTICALS, INC. I - DEFINITIONS 1 II - PRODUCT MANUFACTURE AND SUPPLY 9 2.1???MANUFACTURE AND PURCHA |
|
| November 8, 2022 |
Exhibit 10.6 ARS PHARMACEUTICALS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for RICHARD E. LOWENTHAL This Executive Employment Agreement (this ?Agreement?) is made and entered into effective as of September 14, 2018 (the ?Effective Date?), by and between Richard E. Lowenthal (?Executive?) and ARS Pharmaceuticals, Inc. (the ?Company?). 1. Employment by the Company. 1.1 Position. Executive shall serve as |
|
| November 8, 2022 |
Exhibit 10.12 ARS PHARMACEUTICALS, INC. CONSULTING AGREEMENT EFFECTIVE DATE: September 13, 2018 THIS CONSULTING AGREEMENT (the ?Agreement?) is made as of the Effective Date set forth above by and between ARS Pharmaceuticals, Inc., a Delaware corporation (?Client?), and Marlinspike Group, LLC (?Consultant?). 1. Engagement of Services. Subject to the terms of this Agreement, Consultant agrees to ren |
|
| November 8, 2022 |
Exhibit 3.2 CERTIFICATE OF MERGER MERGING SABRE MERGER SUB, INC., A DELAWARE CORPORATION WITH AND INTO ARS SUBSIDIARY, INC., A DELAWARE CORPORATION Pursuant to Title 8, Section 251 of the General Corporation Law of the State of Delaware ARS Subsidiary, Inc., a Delaware corporation (the ?Company?), does hereby certify as follows: FIRST: Each of the constituent corporations (the ?Constituent Corpora |
|
| November 8, 2022 |
Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, S |
|
| November 8, 2022 |
Exhibit 10.9 ARS PHARMACEUTICALS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for ERIC KARAS This Executive Employment Agreement (this ?Agreement?) is made and entered into effective as of February 16, 2022 (the ?Effective Date?), by and between Eric Karas (?Executive?) and ARS Pharmaceuticals, Inc. (the ?Company?). 1. Employment by the Company. 1.1 Position. Executive?s employment with the Company shall |
|
| November 8, 2022 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 21, 2022 TABLE OF CONTENTS Page SECTION 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 2 1.3 Closing; Effective Time 2 1.4 Certific |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 4, 2022 Date of Report (Date of earliest event reported) ARS Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commissi |
|
| November 8, 2022 |
Exhibit 10.10 ARS PHARMACEUTICALS, INC. EXECUTIVE EMPLOYMENT AGREEMENT For Justin Chakma This Executive Employment Agreement (this ?Agreement?) is made and entered into effective as of June 1st, 2019 (the ?Effective Date?), by and between Justin Chakma (?Executive?) and ARS Pharmaceuticals, Inc. (the ?Company?). 1. Employment by the Company. 1.1 Position. Executive shall serve as the Company?s Chi |
|
| November 8, 2022 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. Confidential COLLABORATION AND DISTRIBUTION AGREEMENT THIS COLLABORATION AND DISTRIBUTION AGREEMENT (the ?Agreement?) is entered into as of March 1st, 2021 (the ?Effective Date?), |
|
| November 8, 2022 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT THIS COLLABORATION AND LICENSE AGREEMENT (the ?Agreement?) is entered into as of April 30, 2020 (the ?Effective Date?), by and between ARS PHAR |
|
| November 8, 2022 |
Exhibit 10.13 MASTER SERVICES AGREEMENT THIS MASTER SERVICES AGREEMENT (hereinafter ?Agreement?) is made as of the 01 July 2022 (?Effective Date?), between ARS Pharmaceuticals, Inc. (?Company?) and Pacific-Link Regulatory Consulting, Inc. (?PLC?). Company and PLC also are each referred to herein individually as ?Party? and collectively as the ?Parties.? BACKGROUND The Company has products in devel |
|
| November 8, 2022 |
Exhibit 10.4 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT ATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. ARS PHARMACEUTICALS, INC. and RECORDATI IRELAND, LTD LICENSE AND SUPPLY AGREEMENT for the finished product ARS-1 TABLE OF CONTENTS SECTION I ? CERTAIN DEFINITIONS 1 1. RECITALS AND |
|
| November 8, 2022 |
Exhibit 10.7 ARS PHARMACEUTICALS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for KATHY SCOTT This Executive Employment Agreement (this ?Agreement?) is made and entered into effective as of February 7, 2022 (the ?Effective Date?), by and between Kathleen Scott (?Executive?) and ARS Pharmaceuticals, Inc. (the ?Company?). 1. Employment by the Company. 1.1 Position. Executive?s employment with the Company sh |
|
| November 8, 2022 |
Exhibit 10.8 ARS PHARMACEUTICALS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for DR. SARINA TANIMOTO This Executive Employment Agreement (this ?Agreement?) is made and entered into effective as of September 14, 2018 (the ?Effective Date?), by and between Dr. Sarina Tanimoto (?Executive?) and ARS Pharmaceuticals, Inc. (the ?Company?). 1. Employment by the Company. 1.1 Position. Executive shall serve as th |
|
| November 8, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SILVERBACK THERAPEUTICS, INC. SILVERBACK THERAPEUTICS, INC. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify: FIRST: The name of the Corporation is Silverback Therapeutics, Inc. SECOND: Th |
|
| November 8, 2022 |
Exhibit 99.1 ARS Pharmaceuticals Closes Merger with Silverback Therapeutics Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy? in the U.S., if Approved neffy? NDA Currently Under FDA Review; PDUFA Anticipated Mid-2023 MAA validated in the European Union Under Review SAN DIEGO ? November 8, 2022 - ARS Pharmac |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Com |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 Silver |
|
| November 2, 2022 |
SILVERBACK THERAPEUTICS, INC. CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (?Agreement?) is made by and between Silverback Therapeutics, Inc., a Delaware corporation, and its successors or assignees (collectively, ?Company?), and Jonathan Piazza (?Consultant?), and is entered into as of September 2, 2022 (the ?Effective Date?). 1. Engagement of Services. Company and Consultant |
|
| November 2, 2022 |
SILVERBACK THERAPEUTICS, INC. CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (?Agreement?) is made by and between Silverback Therapeutics, Inc., a Delaware corporation, and its successors or assignees (collectively, ?Company?), and Valerie Odegard (?Consultant?), and is entered into as of September 2, 2022 (the ?Effective Date?). 1. Engagement of Services. Company and Consultant |
|
| November 2, 2022 |
SILVERBACK THERAPEUTICS, INC. CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (?Agreement?) is made by and between Silverback Therapeutics, Inc., a Delaware corporation, and its successors or assignees (collectively, ?Company?), and the undersigned Laura Shawver, Ph.D. (?Consultant?), and is effective as of September 2, 2022 (the ?Effective Date?). 1. Engagement of Services. Compa |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Com |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 SILVERBACK THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Com |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| October 27, 2022 |
Exhibit 10.1 SECOND AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER AND REORGANIZATION This Second Amendment (this ?Amendment?) to the Agreement and Plan of Merger and Reorganization, dated as of July 21, 2022, by and among Silverback Therapeutics, Inc., a Delaware corporation (?Parent?), Sabre Merger Sub, Inc. a Delaware corporation and wholly owned subsidiary of Parent (?Merger Sub?), and ARS Phar |
|
| October 27, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 SILVERBACK THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Com |
|
| October 21, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2022 SILVERBACK THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction (Commission (IRS Emplo |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2022 SILVERBACK THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction (Commission (IRS Emplo |
|
| October 21, 2022 |
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for Exhibit 99.1 Silverback Therapeutics, Inc. announces the FDA?s acceptance of ARS Pharmaceuticals? NDA for neffy? (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis ? neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approved SEATTLE ? October 21, 2022 ? Silve |
|
| October 6, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (C |
|
| September 30, 2022 |
Exhibit 10.1 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this ?Amendment?) is entered into as of this 27th day of September, 2022, by and between BMR-500 FAIRVIEW AVENUE LLC, a Delaware limited liability company (?Landlord?), and SILVERBACK THERAPEUTICS, INC., a Delaware corporation (?Tenant?). RECITALS A. WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of Jun |
|
| September 16, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| September 16, 2022 |
Kenneth J. Rollins T: +1 858 550 6136 [email protected] September 16, 2022 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Christie Wong, Al Pavot, Joshua Gorsky and Laura Crotty Re: Silverback Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed August 11, 2022 File No. 001-39756 Ladi |
|
| September 16, 2022 |
Exhibit 107 Calculation of Fee Tables Schedule 14A (Form Type) Silverback Therapeutics, Inc. |
|
| September 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Co |
|
| September 2, 2022 |
Exhibit 99.1 April 17, 2020 Russ Hawkinson Via email: [***] Dear Russ, This will confirm the terms under which Silverback Therapeutics, Inc., a Delaware corporation (the ?Company?) has made you an offer of employment: 1. Position and Duties. You will serve as Senior Vice President, Finance and shall perform such duties as are ordinary, customary and necessary in such role (subject to the limitatio |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 Silverback |
|
| August 11, 2022 |
Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 2 TO CELL LINE LICENSE AGREEMENT This Amendment No. 2 (this ?Amendment?) is entered into between Silverback Therapeutics, Inc. (?Licensee?) and WuXi Biologics (Hong Kong) Limited (?WuXi Bi |
|
| August 11, 2022 |
Letter Agreement, by and between the registrant and Jeffrey Pepe, Ph.D., J.D., dated June 6, 2019. exhibit 10.3 Silverback Therapeutics, Inc. 500 Fairview Avenue North Suite 600 Seattle, WA 98109 June 4, 2019 Jeffrey C. Pepe Via email Dear Jeff, This will confirm the terms under which Silverback Therapeutics, Inc., a Delaware corporation (the ?Company?) has made you an offer of employment: 1. Position and Duties. You will serve as Senior Vice President and General Counsel and shall perform such |
|
| August 11, 2022 |
Exhibit 107 Calculation of Fee Tables Schedule 14A (Form Type) Silverback Therapeutics, Inc. |
|
| August 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| August 11, 2022 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 21, 2022 TABLE OF CONTENTS Page SECTION 1. DESCRIPTION OF TRANSACTION A-2 1.1 The Merger A-2 1.2 Effects of the Merger A-2 1.3 Closing; Effective Time A-2 1.4 |
|
| July 21, 2022 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: SILVERBACK THERAPEUTICS, INC., a Delaware corporation; SABRE MERGER SUB, INC., a Delaware corporation; and ARS PHARMACEUTICALS, INC., a Delaware corporation Dated as of July 21, 2022 TABLE OF CONTENTS Page SECTION 1. DESCRIPTION OF TRANSACTION 2 1.1 The Merger 2 1.2 Effects of the Merger 2 1.3 Closing; Effective Time 2 1.4 Certific |
|
| July 21, 2022 |
Exhibit 99.3 On July 21, 2022, Silverback Therapeutics, Inc. (?Silverback?) and ARS Pharmaceuticals, Inc. (?ARS?) hosted an investor conference call at 5:00 pm Eastern Time to discuss the entering into a definitive merger agreement under which ARS will merge with a wholly owned subsidiary of Silverback in an all-stock transaction. The script of the conference call related to such proposed merger i |
|
| July 21, 2022 |
Exhibit 99.1 Silverback Therapeutics and ARS Pharmaceuticals Announce Merger Transaction to support potential commercialization of neffy?, ARS?s needle-free epinephrine nasal spray Well-funded with at least three years of operating runway expected Companies to host conference call today, July 21, 2022, at 5:00 p.m. ET SEATTLE and SAN DIEGO ? July 21, 2022 ? Silverback Therapeutics, Inc. (Nasdaq: S |
|
| July 21, 2022 |
Form of Silverback Therapeutics, Inc. Support Agreement, dated July 21, 2022. Exhibit 10.1 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this ?Agreement?), is made as of July 21, 2022, by and between ARS THERAPEUTICS, INC., a Delaware corporation (the ?Company?) and the Person set forth on Schedule A hereto (the ?Stockholder?). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares of common stock, par value $0.0001 per share (?Parent Shares?), of |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2022 SILVERBACK THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commis |
|
| July 21, 2022 |
Form of Lock-Up Agreement, dated July 21, 2022. Exhibit 10.3 Lock-Up Agreement July 21, 2022 Ladies and Gentlemen: The undersigned (the ?Stockholder?) understands that: (i) SILVERBACK THERAPEUTICS, INC., a Delaware corporation (?Parent?), has entered into an Agreement and Plan of Merger and Reorganization, dated as of July 21, 2022 (the ?Merger Agreement?), with ARS PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?) and SABRE MERGER |
|
| July 21, 2022 |
Internal Silverback Email Communication and FAQ July 21, 2022 Exhibit 99.4 Internal Silverback Email Communication and FAQ July 21, 2022 Dear Colleagues, This afternoon, we announced that earlier today, Silverback Therapeutics, Inc. (?Silverback?) signed an agreement to merge with ARS Pharmaceuticals, Inc. (?ARS?), a San Diego-based biopharmaceutical company developing an intranasally administered epinephrine product called neffy?, the first no-needle, no-in |
|
| July 21, 2022 |
Merger Announcement July 21, 2022 Exhibit 99.2 Forward Looking Statements This presentation contains forward-looking statements which include, but are not limited to, statements regarding expected timing, completion, effects and potential benefits of the proposed merger; the expected cash, cash equivalents and marketable securities of the combined company at closing; the expected ownership percent |
|
| July 21, 2022 |
Form of ARS Pharmaceuticals, Inc. Support Agreement, dated July 21, 2022. Exhibit 10.2 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this ?Agreement?), is made as of July 21, 2022, by and between SILVERBACK THERAPEUTICS, INC., a Delaware corporation (?Parent?) and the Person set forth on Schedule A hereto (the ?Stockholder?). WHEREAS, as of the date hereof, the Stockholder is the holder of the number of shares, par value $0.01 per share (?Company Shares?), of ARS PHARMACEUT |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2022 SILVERBACK THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commis |
|
| July 18, 2022 |
SBTX / Silverback Therapeutics Inc / K2 PRINCIPAL FUND, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Under the Securities Exchange Act of 1934 Silverback Therapeutics, Inc (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82835W108 (CUSIP Number) July 13, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commis |
|
| May 12, 2022 |
Non-Employee Director Compensation Policy, as amended. SILVERBACK THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Silverback Therapeutics, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy for his or |
|
| May 12, 2022 |
Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Exhibit 99.1 Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update SEATTLE ? May 12, 2022 ? Silverback Therapeutics, Inc. (Nasdaq: SBTX) (?Silverback?), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 Silverback |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commiss |
|
| May 6, 2022 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2022 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commissi |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commi |
|
| March 31, 2022 |
Exhibit 99.1 Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results - Strategic realignment to focus resources on SBT8230 for chronic hepatitis B virus (cHBV) and discovery pipeline by discontinuing SBT6050 and SBT6290 clinical oncology programs - On track to complete a Phase 1 regulatory submission for SBT8230 in the fourth quarter of |
|
| March 31, 2022 |
Jones Lang LaSalle 601 Union St. Ste 2800 Seattle, WA 98101 Phone: 206-607-1700 Fax: 206-607-1701 ? Commercial Brokers Association ALL RIGHTS RESERVED Form: SUBLS SubleaseAgreement Rev. 9/2020 Page 1 of 20 SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (?Sublease?) is entered and effective this 1st day of July, 2021, by DELTA DENTAL OF WASHINGTON, a(n) Washington nonprofit corporation, (?Tenant?), and |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 Silverback Ther |
|
| March 31, 2022 |
Silverback Therapeutics, Inc. RSU Award Grant Notice (2020 Equity Incentive Plan) Silverback Therapeutics, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the ?RSU Award?). Your RSU Award is subject to all the terms and conditions as set forth herein and in the Company?s 2 |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2022 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commi |
|
| February 14, 2022 |
SBTX / Silverback Therapeutics Inc / Boxer Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SILVERBACK THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 82835W108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 14, 2022 |
SBTX / Silverback Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Silverback Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 82835W108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Silverback Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82835W108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 27, 2022 |
SBTX / Silverback Therapeutics Inc / U.S. Venture Partners XII, L.P. - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) Silverback Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 82835W108 (CUSIP Number) Dale Holladay c/o U.S. Venture Partners 1460 El Camino Rea |
|
| January 11, 2022 |
Silverback Therapeutics, Inc. | 500 Fairview Avenue N, Suite 600, Seattle, WA 98109 USA | Phone: Silverback Therapeutics, Inc. | 500 Fairview Avenue N, Suite 600, Seattle, WA 98109 USA | Phone: 206-456-2900 January 11, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Margaret Schwartz Re: Silverback Therapeutics, Inc. Registration Statement on Form S-3 Filed: January 3, 2022 File No. 333-261979 Ladies and Ge |
|
| January 3, 2022 |
As filed with the Securities and Exchange Commission on January 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on January 3, 2022 Registration No. |
|
| January 3, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.8 SILVERBACK THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF SILVERBACK THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between SILVERBACK THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association |
|
| January 3, 2022 |
As filed with the Securities and Exchange Commission on January 3, 2022 As filed with the Securities and Exchange Commission on January 3, 2022 Registration No. |
|
| January 3, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 SILVERBACK THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF SILVERBACK THERAPEUTICS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between SILVERBACK THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organiz |
|
| January 3, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 SILVERBACK THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF SILVERBACK THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between SILVERBACK THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association |
|
| January 3, 2022 |
Form of Indenture, between the registrant and one or more trustees to be named. Exhibit 4.3 Silverback Therapeutics, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certifi |
|
| November 10, 2021 |
Jones Lang LaSalle 601 Union St. Ste 2800 Seattle, WA 98101 Phone: 206-607-1700 Fax: 206-607-1701 ? Commercial Brokers Association ALL RIGHTS RESERVED Form: SUBLS SubleaseAgreement Rev. 9/2020 Page 1 of 20 SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (?Sublease?) is entered and effective this 1st day of July, 2021, by DELTA DENTAL OF WASHINGTON, a(n) Washington nonprofit corporation, (?Tenant?), and |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Co |
|
| November 10, 2021 |
Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update EX-99.1 2 d200650dex991.htm EX-99.1 Exhibit 99.1 Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update SEATTLE – November 10, 2021 – Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutic |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 Silver |
|
| September 16, 2021 |
Exhibit 99.1Exhibit 99.1 Forward-looking statements and disclaimers Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of any of its contents is prohibited. This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future |
|
| September 16, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2021 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (C |
|
| September 13, 2021 |
EX-99.1 2 d220449dex991.htm EX-99.1 Exhibit 99.1 Title: Results of an ongoing Phase 1/1b study of SBT6050 as monotherapy and combined with pembrolizumab in patients with advanced HER2-expressing or amplified solid tumors Samuel J. Klempner1, Muralidhar Beeram2, Dhanusha Sabanathan3, Arlene Chan4, Erika Hamilton5, Sherene Loi6, Do-Youn Oh7, Leisha A. Emens8, Amita Patnaik2, Jeong Eun Kim9, Yeon Hee |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (C |
|
| August 12, 2021 |
Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update EX-99.1 2 d214895dex991.htm EX-99.1 Exhibit 99.1 Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update SEATTLE – August 12, 2021 – Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 Silverback |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Comm |
|
| July 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2021 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commiss |
|
| June 9, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commiss |
|
| May 13, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commiss |
|
| May 13, 2021 |
Silverback Therapeutics Reports First Quarter 2021 Financial Results EX-99.1 2 d355932dex991.htm EX-99.1 Exhibit 99.1 Silverback Therapeutics Reports First Quarter 2021 Financial Results SEATTLE – May 13, 2021 – Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chr |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 Silverback Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39756 81-1489190 (State or other jurisdiction of incorporation) (Commi |
|
| March 29, 2021 |
As filed with the Securities and Exchange Commission on March 29, 2021 Registration No. |
|
| March 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-397 |
|
| March 29, 2021 |
EX-99.1 2 d114709dex991.htm EX-99.1 Exhibit 99.1 Silverback Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Updates Initiated SBT6050 clinical development, with pharmacological activity demonstrated in the first dose cohort Advanced preclinical development of SBT6290 and declared SBT8230 as the development candidate for chronic hepatitis B virus progra |
|
| March 29, 2021 |
EX-10.16 3 d109083dex1016.htm EX-10.16 Exhibit 10.16 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1 TO CELL LINE LICENSE AGREEMENT This Amendment No. 1 (this “Amendment”) is entered into between Silverback Therapeutics, Inc. (“Licensee”) and WuXi |
|
| March 29, 2021 |
Description of Registrant’s Common Stock. EX-4.6 2 d109083dex46.htm EX-4.6 Exhibit 4.6 DESCRIPTION OF COMMON STOCK The following summary description of the common stock of Silverback Therapeutics, Inc. (we, our or us) is based on the provisions of our amended and restated certificate of incorporation, as well as our amended and restated bylaws, and the applicable provisions of the Delaware General Corporation Law. This information is qual |
